Enanta Product EPD-305 Has Promising Results for the Treatment NASH

Enanta Positive Results of EPD-305 for NASH

Enanta (ENTA) has positive results from the ARGON-1 Phase 2 study evaluating the safety, tolerability pharmacokinetics and efficacy of its product EPD-305 for the treatment of non-alcoholic steatohepatitis (NASH).  

The results met the primary endpoint of ALT reduction at week 12; in the . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.